The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin
| Autor: | Nagendra R. Pokala, Ildiko Lingvay, Xilong Li, Anna Vanderheiden, Beverley Adams-Huet, Lindsay B. Harrison |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 03 medical and health sciences 0302 clinical medicine Endocrinology Insulin resistance Double-Blind Method Weight loss Internal medicine Post-hoc analysis Internal Medicine Humans Insulin Medicine In patient 030212 general & internal medicine Aged Glycated Hemoglobin Dose-Response Relationship Drug business.industry Liraglutide nutritional and metabolic diseases Middle Aged medicine.disease Treatment Outcome Diabetes Mellitus Type 2 Baseline characteristics Drug Therapy Combination Female medicine.symptom business Body mass index medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 19:1454-1457 |
| ISSN: | 1462-8902 |
| DOI: | 10.1111/dom.12939 |
| Popis: | In patients requiring high-dose insulin treatment, a randomized, double-blind, placebo-controlled study showed that liraglutide improved glycaemic control and treatment satisfaction while promoting weight loss. We performed a post hoc analysis to evaluate if patients' baseline characteristics impact the efficacy of liraglutide, and which outcomes correlate with treatment satisfaction. We used regression analysis to model the change in HbA1c and weight, with treatment assignment and baseline characteristics [HbA1c, age, body mass index (BMI), total daily dose (TDD) of insulin, duration of insulin treatment, and type of insulin regimen] as independent variables. Improvement in HbA1c was best predicted by treatment with liraglutide, followed by higher baseline HbA1c, BMI and age. Changes in weight were only associated with liraglutide treatment, independent of all baseline characteristics. Improvement in HbA1c was the only significant predictor of improvement in treatment satisfaction, while weight loss, change in TDD of insulin and rate of hypoglycaemia did not influence treatment satisfaction. In patients treated with high-dose insulin, liraglutide significantly improved glycaemic control and led to weight loss regardless of patients' baseline characteristics. Improvement in HbA1c was the most important predictor of patients' treatment satisfaction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text